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Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: A bibliographic review
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Introduction. To report a case of Primary Ocular Adnexal MALT Lymphoma (POAML) and perform a review of the literature about
this neoplasia focusing on the role of radiotherapy and its toxicity. Case presentation A 78-year-old man with a conjunctival
POAML, without systemic disease, was treated with intralesional Rituximab into a clinical trial, with an initial good response but
local progression associated to haemorrhage after a few cycles. The patient underwent salvage radiotherapy using a direct 6MeV
electrons ﬁeld with a circular 5 cm applicator, receiving a total dose of 30 Gy (2-Gy per fraction) achieving a good response. The
acute toxicity was mild periorbital erythema, and excessive tearing or swelling which did not require any treatment intervention.
Results. POAML is a rare disorder that represents approximately 8% of all extranodal lymphomas and has a relatively indolent
course, remaining localized during a long time. Although there is no consensus regarding to the initial management of POAML,
radiotherapy has been considered themost effective treatment for localized disease. Radiotherapy for localizedMALT lymphoma,
despite offering an excellent local control, might not be useful in preventing systemic relapses, occurring in 5–45% of patients.
The efﬁcacy of the combination of radiotherapy and chemotherapy has not been fully investigated. There are large differences
in the total doses reported, ranging from 20 to 54Gy, although most authors recommend a total dose of 30–34Gy with 1.5–2Gy
per fraction. The delivery of 30Gy in conventional fractions to the orbit is considered safe, except for the potential development
of cataracts. Although MALT lymphomas occasionally produce distant involvement, primary tumors do not usually inﬁltrate the
surrounding normal tissues. Therefore, it is not always necessary to include the whole orbit in the radiation ﬁeld. In this case
the whole conjunctiva was irradiated to avoid the local relapse.
Conclusion. Radiation therapy is effective and safe for patients with POAML, achieving a good local control with a reasonable
toxicity rate. Although some patients developed cataracts after irradiation, visual acuity was preserved in all series. A total dose
of 30Gy may be recommended for the treatment, but further investigations are required to deﬁne the optimal dose.
http://dx.doi.org/10.1016/j.rpor.2013.03.340
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Introduction. According to the relevant literature extranodal primary lymphomas of parotid are rare. Moreover if we consider that
its incidence is very lowand that the only cases reported are usually non-Hodgkin lymphomas associatedwith immunodeﬁciency
(HIV) or autoimmune diseases (Sjögren). Collected in world literature are published about 30 cases of primary Hodgkin’s disease
of parotid. The most frequent variety lymphocyte-predominant HD. Because of the rarity of the variety lymphocyte-rich classical
HD (<5% total), this is one of the few cases reported to date, CASE a man of 44 years old with no prior medical or surgical relevant
history. He consulted the G.P. about a mass located in the right parotid region without B symptoms in May/2012 then He was sent
to the referral hospital to assess possibility of Maxillofacial Surgery. The diagnosis of low grade B-cell lymphoma suspected after
FNA. Subsequently, it was recommended eliminating this right parotid mass held on 07.12.2012, under general anesthesia, using
preauricular incision and enucleation of a node approx. 2 cm and located in the upper lobe of the right parotid. After histological
examination macroscopic a lymph node was identiﬁed and removed completely covered by a capsule of ﬁbrous tissue with tissue
debris salivary. Microscopic histological analysis veriﬁed the presence of Hodgkin lymphoma, lymphocyte-rich as now classiﬁed
2009. Following the usual protocol, we proceeded to do the staging for what was useful PET-CT. This study was conducted in
September 2012 and identiﬁes a pathologically increased glucose metabolism in the right parotid gland of 2.7 cm×1.5 cm. Up
to 6 SUV. The rest of the extension study was negative for detecting lymphoma. After the study was considered as Hodgkin
lymphoma stage I AE parotid Treatment: The patient began receiving systemic chemotherapy from 14/10/2012 until completing
4 cycles of ABVD chemotherapy scheme, with complete metabolic PET TAC response. Subsequently, the patient was treated with
involved ﬁeld radiotherapy. The patient reaching 30Gy as usual fractionation with excellent tolerance.
http://dx.doi.org/10.1016/j.rpor.2013.03.341
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Introduction. Lymphomas may rarely be detected as a form of primary lung disease, although they usually affect the lungs sec-
ondarily. The natural history of PPNHL appears to be slow compared with other low grade lymphomas, and their treatment is
controversial.
Objective. Description of a case of primary pulmonary Lymphoma in a woman of 70 years.
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Case report. 70 years old woman who presented a syncope clinic in June 2003 Chest X: increased density in the left upper lobe of
the left lung. Chest CT (24/09/2003): 6 cm×6.5 cm×3.5 cm mass in LSI. Fibroscopy: No evidence of neoplastic cells. Percutaneous
biopsy: diffuse lymphoid proliferation with little cellular atypia, compatible with non-Hodgkin lymphoma of low grade malig-
nancy. Sign chemotherapy with partial response on CT and PET with low activity. Adjuvant radiotherapy (35Gy at 1.8Gy/session)
with cobalt bomb. CT Post-Radiation: No evidence of tumor remaining. Subsequent revisions since nowday: no evidence of
disease on imaging test.
Discussion. Primary pulmonary non-Hodgkin’s lymphoma represent <1% of primary malignant lung tumors. PPL might be of
various histopathological types and the most frequently encountered type is the MALT. PPNHL has various clinical symptoms and
that 37.5–50% of patients are asymptomatic. Bronchoscopy may be of limited value, as diagnosis based on endobronchial changes
is rare while the positive predictive rate of a puncture biopsy under CT guidance is only 25%. PPL is generally diagnosed through
an evaluation of large surgical tissue biopsies. Their treatment is controversial and some recent series did not demonstrate any
difference in survival among patients receiving local-regional therapy alone (surgical intervention or irradiation), chemotherapy,
or a combination.
Conclusions. Primary pulmonary non-Hodgkin’s lymphoma are associated with a good prognosis. Chemotherapy (CNOP) plus
adjuvant radiotherapy is shown as a therapeutic option with low toxicity and long survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.342
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Introduction. Primary thyroid lymphoma occurs in less than 3% of all non-Hodgkin’s extranodal lymphoma. To perform a retro-
spective and descriptive study of the patients treated in our centre.
Methods. Two cases of primary thyroid lymphoma that underwent to radiotherapy are described. Both of them was diffuse large B-
cell lymphoma, which is the most common type of this pathology. The ﬁrst case was 74 year-old woman. She was classiﬁcated as
stage IIA-E and was performed thyroid biopsy. The second case was 65 year-old woman. She was classiﬁcated as stage IA-E and
was performed left hemithyroidectomy. Both patients have received chemotherapy with R-CHOP 4× cycles and radiotherapy.
Radiation ﬁelds included thyroid gland (left hemithyroidectomy surgical bed in the second patient), neck nodes and upper
mediastinum nodes to a total dose of 36Gy (5×2Gy). Acute and late toxicity was assessed using the RTOG/EORTC criteria.
Results. With a median follow-up of 9 months, both patients are free of disease. One patient experienced grade I mucositis and
the other one grade II mucositis during radiotherapy. There were no late toxicity.
Conclusion. The typical patient is female and ederly as the literature reports. Therapeutic management is distinct from other
thyroid neoplasias and include surgery, chemotherapy and radiotherapy.
http://dx.doi.org/10.1016/j.rpor.2013.03.343
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Introduction. Primary cutaneous lymphomas (CL) represent 19% of extranodal non-Hodgkin lymphomas (NHLs). Approximately
one-fourth of cutaneous lymphomas are B-cell derived and are generally classiﬁed into three distinct subgroups: primary cuta-
neous follicle-center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse
large B-cell lymphoma, leg type (PCLBCL, LT). Both PCFCL and PCMZL are indolent lymphomas that may be successfully managed
with local radiation therapy.
Objectives. We reported one case of primary cutaneous marginal PCMZ in the leg treated by VMAT.
Methods. A 36 years-old man started with multiple nodes and itchiness in his right left. Histological analysis and immunohis-
tochemical staining of four adequate skin biopsies showed the following phenotype: CD20, BCL2+; CD23, CD10, BCL6+ in some
cells. Ki67: +15%. B-lymphoma between follicular and marginal. Lymphoma staging estimated a 5-year disease-speciﬁc survival
rate of 95%. The Ann Arbor staging system: IE. The ISCL/EORTC: T2c all-disease-encompassing in a 30-cm diameter circular.
Results. An aquaplastmask was then prepared, molded to the leg of the patient, and locked to the treatment table. A CT scan of
3mm thick slices of the region was subsequently obtained. The optimization constraints were to deliver 100% of the prescribed
dose, V95: 99.1%-V107: 3.3%, of the target volume and to restrict the target volume receiving more than 110% of the prescribed
dose to 0.2%. The prescription dose was 30Gy. We included a 5 cm margin of clinically normal skin within the target volume.
Bolus is needed to increase the dose to the skin surface to 95%, typically 1 cm of bolus is needed for using 6 MV to give photons
a surface dose of >95% and a depth dose 10mm.
Conclusions. VMAT is an appropriate technique for treating cutaneous lymphomas.
http://dx.doi.org/10.1016/j.rpor.2013.03.344
